clinical trial · NCT07375758
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Beijing Mabworks Biotech Co., Ltd.·phase2·recruiting·n = 130
Immunoglobulin A NephropathyMIL116Matching Placebo
brief summary
This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
started
Feb 5, 2026
primary completion
Jun 1, 2028
completion
Jun 1, 2029
last updated
Apr 13, 2026
official title
A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol